LQDA (Liquidia) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LQDA Liquidia Corp LQDA
67 GF Score
Price $79.94
GF Value $235.75
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

LQDA
67GF Score
Liquidia Corp LQDA
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $79.94 is trading 66.1% below its estimated GF Value™ of $235.75. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Interest Received:
  • GF Value™: $235.75 vs. price of $79.94 (66.1% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score

Get the complete analysis for LQDA

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.94
Price
$235.75
GF Value